All In Biotech

Drug Trial Radar · NCT00673205

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Dec 10, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,588 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,588

Actual

Start

Sep 1995

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.

Conditions

  • Non-Metastatic Prostate Cancer

Interventions

  • BicalutamideDrug

    150mg p.o. daily

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to clinical progressionTime frame: Throughout study period
  2. Tolerability in terms of adverse events and laboratory parametersTime frame: Throughout study period

Locations

128 sites in 16 countries. Site status is shown where the registry gives one.

  • Research Site

    Wooloongabba, Queensland, Australia

  • Research Site

    East Melbourne, Victoria, Australia

  • Research Site

    Graz, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Mistelbach, Austria

  • Research Site

    Oberwart, Austria

  • Research Site

    Sankt Pölten, Austria

  • Research Site

    Antwerp, Belgium

  • Research Site

    Bruges, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Kortrijk, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Mons, Belgium

  • Research Site

    Ostend, Belgium

  • Research Site

    Seraing, Belgium

  • Research Site

    Brno, Czechia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Berlin, Germany

  • Research Site

    Bonn, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Freiburg im Breisgau, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Jena, Germany

  • Research Site

    Lübeck, Germany

  • Research Site

    Lüdenscheid, Germany

  • Research Site

    Mannheim, Germany

  • Research Site

    München, Germany

  • Research Site

    Regensburg, Germany

  • Research Site

    Sigmaringen, Germany

  • Research Site

    Budapest, Hungary

  • Research Site

    Miskolc, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Dublin, Ireland

  • Research Site

    Haifa, Israel

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Tel Aviv, Israel

  • Research Site

    Tel HaShomer, Israel

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.